Vascular calcification promotes a pre-thrombotic state in patients on vitamin K-antagonist (VKA). Patient data include 54 patients on VKA (acenocoumerol) treatment with a mean duration of 44 ± 26 month. VKA treated patients with coronary calcification (Agatston score > 0; n = 35) compared to no coronary calcification (Agatston score = 0; n = 19) showed no difference on circulating TAT levels (B), but significantly increased circulating FIXa:AT levels (A). Dividing the Agatston scores >0 in low (Agatston score 1–50) and high (150–647) did not show any significance for TAT levels (D) or FIXa:AT (C). Data were analysed using Mann–Whitney U test.